Table 6.
Gene Fusions | ALL | AML | CLL | CML | MDS | Other Leukemias | Others | Subtotal |
---|---|---|---|---|---|---|---|---|
RUNX1-RUNX1T1 | 19 (18)a | 1 (0)a | 1 | 21 (19) | 1 | 22 (20) | ||
AML1-MDS/EVII/MTG16 | 1 | 1 | 1 | |||||
BCR-ABL | 5 (4)a | 37 (38)b | 42 (42) | 42 (42) | ||||
CBFβ-MYH11 | 5 | 5 | 5 | |||||
E2A-PBX1 | 7 | 7 | 7 | |||||
FIP1L1-PDGFRA | 1 | 1 | 1 | 2 | ||||
MLL-AF4 | 3 | 3 | 1 | 4 | ||||
MLL-AF6/AF10/ELL/ENL | 1 | 3 | 4 | 3 | 7 | |||
MLL-AF9 | 1 | 1 | 2 | 2 | ||||
NPM-MLF1 | 1 | 1 | 1 | |||||
PML-RARα | 43 | 1 | 44 | 44 | ||||
SIL-TAL1 | 2 | 1 | 3 | 2 | 5 | |||
TEL-AML1 | 3 | 3 | 3 | |||||
TEL-PDGFRB | 1 | 1 | 1 | |||||
Subtotal | 20 (19) | 75 (74) | 0 | 40 (40) | 3 | 138 (136) | 8 | 146 (144) |
No fusion | 40 (41) | 33 (34) | 15 | 0 (1) + 1 (0) | 30 | 119 (121) | 80 | 199 (201) |
Total | 60 | 108 | 15 | 41 | 33 | 257 | 88 | 345 |
% (fusion/total) by PCR | 33.3% | 69.4% | 0.0% | 97.6% | 9.1% | 53.7 (52.9)% | 9.1% | 42.3 (41.7)% |
Numbers in parentheses are predicted by cytogenetic analysis
acytogenetic-negative, PCR-positive
bcytogenetic-positive PCR-negative cases